Experimental CRISPR treatment reportedly cut LDL cholesterol 52.5% after a year in four highest-dose patients

ScienceDaily reports that a single dose of an experimental CRISPR treatment lowered LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. A post citing CNN says four of the trial’s 15 participants received the highest dose; after one year, their LDL was down 52.5% and triglycerides were down 47.8%. The post says researchers reported no serious treatment-related adverse events during the first 12 months and plan 15 years of safety follow-up.